Sertraline exposure leads to small left heart syndrome in adult mice

Pediatric Research

Volumn 73, Issue 3, 2013, Pages 286-293

  Haskell, Sarah E ^a   Hermann, Gregory M ^a   Reinking, Benjamin E ^a   Volk, Kenneth A ^a   Peotta, Veronica A ^a   Zhu, Vivian ^a   Roghair, Robert D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN; SEROTONIN TRANSPORTER; SERTRALINE;

ADRENERGIC SYSTEM; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLE; HEART DISEASE; HEART LEFT VENTRICLE VOLUME; HEART RATE; HEART RATE VARIABILITY; HEART STROKE VOLUME; MALE; MOUSE; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; ECHOCARDIOGRAPHY; HEART RATE; HYPOPLASTIC LEFT HEART SYNDROME; MICE; MICE, INBRED C57BL; NOREPINEPHRINE; ORGAN SIZE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TELEMETRY;

EID: 84874040296     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.183     Document Type: Article

References (45)

1. IMS Health. National Prescription Audit. Parsippany, NJ: IMS, 2010.
2. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194.e1-5.
3. Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008;65:600-6.
4. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using populationbased linked health data. Arch Gen Psychiatry 2006;63:898-906.
5. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH Jr, Watson WJ. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 2008;28:714-6.
6. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-6.
7. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6.
8. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83.
9. Greene MF. Teratogenicity of SSRIs-serious concern or much ado about little? N Engl J Med 2007;356:2732-3.
10. Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002;51:443-53.
11. Oberlander TF, Grunau R, Mayes L, et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008;84:689-97.
12. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005;115:411-25.
13. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008;28:199-207.
14. Shanahan NA, Holick Pierz KA, Masten VL, et al. Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry 2009;65:401-8.
15. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47-57.
16. Nalivaiko E, Sgoifo A. Central 5-HT receptors in cardiovascular control during stress. Neurosci Biobehav Rev 2009;33:95-106.
17. Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res 2009;1293:13-23.
18. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First- trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
19. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
20. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res Part A Clin Mol Teratol 2009;85:837-41.
21. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
22. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003;21:417-24.
23. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008;3:e2782.
24. Clubb FJ Jr, Bishop SP. Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Lab Invest 1984;50:571-7.
25. Walsh S, Pontén A, Fleischmann BK, Jovinge S. Cardiomyocyte cell cycle control and growth estimation in vivo-an analysis based on cardiomyocyte nuclei. Cardiovasc Res 2010;86:365-73.
26. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 2010;141:122-31.
27. Ungvari Z, Pacher P, Koller A. Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol 2000;35:849-54.
28. Côté F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004;10:232-8.
29. Nebigil CG, Choi DS, Dierich A, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 2000;97:9508-13.
30. Nebigil CG, Hickel P, Messaddeq N, et al. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation 2001;103:2973-9.
31. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 2002;71:667-80.
32. Kummet GJ, Haskell SE, Hermann GM, et al. Neonatal SSRI exposure programs a hypermetabolic state in adult mice. J Nutr Metab 2012;2012: 431574.
33. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-75.
34. Muneoka K, Shirayama Y, Takigawa M, Shioda S. Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem Res 2009;34:542-55.
35. Halberstadt AL, van der Heijden I, Ruderman MA, et al. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 2009;34:1958-67.
36. Thornburg K, Jonker S, O'Tierney P, et al. Regulation of the cardiomyocyte population in the developing heart. Prog Biophys Mol Biol 2011;106:289-99.
37. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
38. Johnson RD, Lewis RJ, Angier MK. The distribution of fluoxetine in human fluids and tissues. J Anal Toxicol 2007;31:409-14.
39. Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009;31:42-56.
40. Kelly RH, Russo J, Holt VL, et al. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol 2002;100:297-304.
41. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
42. Kronik G, Slany J, Mösslacher H. Comparative value of eight M-mode echocardiographic formulas for determining left ventricular stroke volume. A correlative study with thermodilution and left ventricular singleplane cineangiography. Circulation 1979;60:1308-16.
43. Roghair RD, Segar JL, Volk KA, et al. Vascular nitric oxide and superoxide anion contribute to sex-specific programmed cardiovascular physiology in mice. Am J Physiol Regul Integr Comp Physiol 2009;296:R651-62.
44. Hrate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-65.
45. Stauss HM. Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 2007;34:362-8.